How to Choose a Dermatology CRO: 7 Critical Questions for Clinical Trial Sponsors 

Selecting a dermatology CRO for  clinical trial is not simply a matter of finding a provider with experience in skin diseases. The real challenge is identifying a partner capable of translating therapeutic expertise into reliable recruitment forecasts, consistent clinical assessments, and effective study execution. 

Dermatology trials introduce operational complexities that are easy to underestimate. Disease severity can fluctuate, eligibility criteria may exclude otherwise suitable patients, and efficacy assessments often depend on clinical judgment. Across multicenter studies, even modest differences in assessment practices can complicate the interpretation of treatment effects. 

For pharmaceutical and biotechnology sponsors, choosing the right dermatology CRO therefore requires a closer examination of how a prospective partner approaches these risks. 

The following seven questions provide a practical framework for evaluating CRO capabilities before committing to a clinical development partnership. 

Does the CRO Have Experience in Your Specific Dermatological Indication?

General dermatology experience does not necessarily translate into expertise across every dermatological indication. 

A clinical trial in plaque psoriasis may involve different recruitment considerations, endpoints, treatment histories, and site requirements than a study in atopic dermatitis, alopecia areata, or hidradenitis suppurativa. 

For example, psoriasis trials frequently use the Psoriasis Area and Severity Index (PASI) and static Physician’s Global Assessment (sPGA), while atopic dermatitis studies commonly incorporate the Eczema Area and Severity Index (EASI), Investigator’s Global Assessment (IGA), and patient-reported symptom measures. 

These differences affect more than protocol design. They influence investigator training, eligibility assessment, site selection, and ongoing data review. 

When evaluating a dermatology CRO, sponsors should look beyond the number of studies completed and ask: 

• Which dermatological indications has the CRO supported? 

• What phases and types of investigational therapies were involved? 

• Did the CRO manage full-service operations or a defined portion of the study? 

• What recruitment, start-up, and operational challenges arose, and how were they addressed? 

Relevant experience should be demonstrated through specific examples rather than broad claims of therapeutic expertise. 

The key consideration: A CRO’s ability to explain how previous dermatology trial experience informs decisions in the proposed study is more valuable than an extensive but undifferentiated project list. 

How Does the Dermatology CRO Ensure Consistency in Clinical Assessments?

In dermatology, reliable clinical outcome assessments are essential to generating credible study results. Many endpoints rely on investigator evaluations of visible disease characteristics, including erythema, scaling, and lesion severity, making consistency across sites particularly important. 

The Harmonising Outcome Measures for Eczema (HOME) initiative highlights the importance of standardization, recommending validated instruments such as EASI for clinical signs and the Patient-Oriented Eczema Measure (POEM) for symptoms. 

An experienced dermatology CRO should ensure consistent assessor training, calibration, and quality oversight. For studies involving clinical photography or centralized image review, standardized imaging procedures are equally important. These measures should be established before patient enrollment begins. 

The key consideration: Ask how the CRO will identify and address assessment inconsistencies during the trial, not simply whether investigators will receive initial training. 

Are Patient Recruitment Forecasts Based on Realistic Feasibility Data?

Despite the high prevalence of many dermatological conditions, identifying eligible trial participants can be challenging. Eligibility often depends on disease severity, treatment history, washout requirements, and comorbidities, significantly narrowing the patient pool. As a result, recruitment forecasts based primarily on disease prevalence or investigator estimates may be overly optimistic. 

An experienced dermatology CRO should evaluate feasibility at the protocol and site levels, including: 

• The number of potentially eligible patients under the proposed inclusion and exclusion criteria. 

• Historical enrollment performance in comparable studies. 

• Competing trials and available treatment alternatives. 

• Screening procedures and likely reasons for screen failure. 

• Country-specific start-up requirements and recruitment opportunities. 

Feasibility should also be revisited when screening data reveal that initial assumptions were inaccurate. 

A real-world example: Rescuing a pediatric psoriasis trial 

Cromos Pharma’s experience in a Phase II pediatric psoriasis study demonstrates the value of targeted feasibility and site selection. 

After four months, only 4 of the planned 66 patients had been enrolled in the United States. Brought in as a rescue CRO, Cromos Pharma selected five sites in Georgia and Ukraine based on recruitment potential and operational feasibility. 

The result: 58 patients enrolled within five months at Cromos Pharma’s participating sites, helping the study reach its enrollment target. 

The key consideration: Sponsors should ensure recruitment forecasts are evidence-based and that their CRO has a clear contingency plan if enrollment falls behind schedule. 

Can the Dermatology CRO Support an Endpoint Strategy That Meets Regulatory and Patient Needs?

Selecting appropriate endpoints requires balancing clinical relevance, measurement reliability, patient experience, and regulatory expectations. Improvements in visible skin symptoms may not fully reflect changes in itching, discomfort, or quality of life. 

The FDA’s October 2025 guidance on Clinical Outcome Assessments emphasizes selecting measures that are fit for purpose and meaningful to patients. 

Sponsors must ensure assessment tools are appropriate for the target population and can be applied consistently across sites. A dermatology CRO should help identify operational risks associated with their implementation. 

The key consideration: Endpoints must be both scientifically valid and feasible to assess reliably throughout the trial. 

Can the CRO Recruit a Patient Population That Reflects the Disease?

Patient representation is particularly important in dermatology because skin conditions may present differently across skin tones, and disease prevalence can vary among demographic groups. 

Yet clinical research has not consistently reflected this diversity. 

A 2023 study published in the Journal of the American Academy of Dermatology examined 246 dermatology clinical trials completed in the United States between 2017 and 2021. The researchers found that several racial and ethnic groups were underrepresented, including Black/African American and Hispanic or Latino populations. 

These findings raise practical questions about site networks, recruitment strategies, and the generalizability of study findings. For sponsors, an inclusive recruitment strategy may require: 

• Selecting sites that serve patient populations relevant to the disease’s epidemiology. 

• Evaluating barriers related to travel, visit schedules, language, and access to research. 

• Ensuring patient-facing materials are accessible and appropriate for the target population. 

• Training assessors to recognize disease manifestations across different skin tones. 

The appropriate recruitment strategy should reflect the indication, target population, scientific objectives, and applicable regulatory requirements. 

The key consideration: Patient representation should be addressed during feasibility and site selection, not treated solely as a recruitment metric after enrollment begins. 

How Does the CRO Manage Operational Risks Before They Affect Study Timelines?

Operational risks in dermatology trials are closely interconnected. Restrictive eligibility criteria can increase screen failures, inconsistent assessments can compromise data quality, and demanding visit schedules may affect patient retention. 

The ICH E6(R3) Good Clinical Practice guideline emphasizes a risk-based approach to trial management, focusing on factors critical to study quality. 

Key indicators to monitor include: 

• Screen failure and enrollment rates by site. 

• Site activation delays. 

• Missing or inconsistent clinical assessments. 

• Protocol deviations and patient discontinuations. 

An experienced dermatology CRO should proactively monitor these indicators, identify emerging risks, and implement timely corrective actions. 

The key consideration: Sponsors should evaluate how the CRO identifies, escalates, and resolves operational issues before they affect study timelines or data quality. 

Does the CRO Offer an Operating Model That Fits Your Development Program?

Dermatology trials require different outsourcing models depending on the sponsor’s capabilities, development stage, and geographical scope. Some sponsors need full-service clinical trial management, while others require support with specific functions such as site feasibility, monitoring, data management, or patient recruitment. 

When evaluating dermatology CRO services, sponsors should consider: 

• Which activities will be managed by the CRO or subcontractors? 

• How will responsibilities, communication, and decision-making be coordinated? 

• Can the operating model adapt as the clinical program evolves? 

The right CRO partner should offer a delivery model aligned with the sponsor’s needs, supported by clear accountability and effective oversight. 

The key consideration: Evaluate the CRO’s proposed team, governance structure, and operational flexibility, not just its range of services. 

Beyond the Proposal: What Really Defines a Strong Dermatology CRO Partnership? 

Choosing a dermatology CRO is ultimately a decision about execution.Therapeutic expertise matters, but it must translate into credible feasibility assumptions, reliable assessments, effective site oversight, and timely operational decisions.A strong partner should be able to demonstrate how it identifies potential challenges before they affect study performance and how it responds when initial assumptions prove incorrect. 

For sponsors, the most revealing questions are often not about what a CRO promises to deliver, but how it plans to deliver it, what evidence supports that plan, and what happens when conditions change.  

Cromos Pharma supports clinical development across multiple therapeutic areas, including dermatology, combining therapeutic knowledge with clinical operations expertise and feasibility-driven recruitment strategies. Our experience in complex clinical programs, including the successful recruitment rescue of a Phase II pediatric psoriasis study, demonstrates the value of adapting study execution to real-world operational conditions. 

Explore our dermatology CRO capabilities or contact Cromos Pharma to discuss your clinical development needs.